Simon Property Group Inc
Change company Symbol lookup
Select an option...
SPG Simon Property Group Inc
JNJ Johnson & Johnson
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
WMT WALMART STORES INC
BROG Brooge Holdings Ltd
EMRAF Emera Inc
PPL PPL Corp
PG Procter & Gamble Co
CLOU Global X Cloud Computing ETF Global X Cloud Computing ETF
GDRX Goodrx Holdings Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Value
Company profile

Simon Property Group, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company owns, develops and manages retail real estate properties, which consist primarily of malls, Premium Outlets and The Mills. Simon Property Group, L.P. (Operating Partnership), is the Company's partnership subsidiary that owns all of its real estate properties and other assets. As of December 31, 2016, the Company owned or held an interest in 206 income-producing properties in the United States, which consisted of 108 malls, 67 Premium Outlets, 14 Mills, four lifestyle centers, and 13 other retail properties in 37 states and Puerto Rico. As of December 31, 2016, it had redevelopment and expansion projects, including the addition of anchors, big box tenants, and restaurants, underway at 27 properties in the United States and it had one outlet and one other retail project under development.

Postmarket

Last Trade
Delayed
$83.22
0.65 (0.79%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$82.57
Day's Change
-2.98 (-3.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
86.90
Day's Low
82.40
Volume
(Light)
Volume:
6,983,693

10-day average volume:
8,774,595
6,983,693

UPDATE: A study testing Lilly's antibody treatment and remdesivir is paused

3:24 pm ET October 13, 2020 (MarketWatch)
Print

Shares of Eli Lilly & Co. (LLY) tumbled 3.1% in trading on Tuesday after the drug maker confirmed a data safety monitoring board had paused enrollment in a clinical study testing its experimental COVID-19 monoclonal antibody treatment in combination with Gilead Sciences Inc.'s (GILD) remdesivir. "Safety is of the utmost importance," a company spokesperson said in an email. The New York Times had first reported (https://www.nytimes.com/live/2020/10/13/world/coronavirus-covid/eli-lilly-antibody-trial-is-paused-because-of-potential-safety-concerns%7CNEW) Tuesday afternoon that the trial had been paused due to safety concerns. The trial, which is sponsored by the National Institutes of Health, is testing Lilly's monoclonal antibody treatment, LY-CoV555, in combination with remdesivir, an antiviral drug that has demonstrated that it can reduce recovery times in COVID-19 patients. Lilly said last week that it had submitted a request for an emergency use authorization to the Food and Drug Administration for LY-CoV555 as a standalone treatment based on findings (http://www.marketwatch.com/story/shares-of-lilly-gain-as-it-discloses-promising-interim-findings-for-covid-19-antibody-treatment-2020-09-16) from a separate trial evaluating the investigational therapy in patients with mild to moderate symptoms. The pause is notable for two reasons. Lilly's investigational antibody drug is similar to the Regeneron Pharmaceuticals Inc.'s experimental antibody treatment that was prescribed to President Donald Trump. It is also the third major clinical trial in this pandemic to be paused for safety reasons, which experts say is a common occurrence but likely one being scrutinized given the lack of treatment or prevention options against the coronavirus. Stat News reported Monday (https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/%7CNEW) that Johnson & Johnson (JNJ) had paused its COVID-19 vaccine trial over an "unexplained illness," and AstraZeneca had halted a trial (http://www.marketwatch.com/story/astrazeneca-stock-falls-as-drugmaker-pauses-vaccine-trial-after-volunteers-unexplained-illness-2020-09-09%7CNEW) for its vaccine candidate in September for the same reason. Lilly's stock has gained 13.9% so far this year, while the S&P 500 is up 9.4%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 13, 2020 15:24 ET (19:24 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.